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ABSTRACT 
The presence of donor specific anti -HLA antibodies is generally a contraindication for transplantation and 
nowadays the identification of these antibodies are part of most pre -transplantation evaluations. In Portugal, 
the implemented protocol for registration and maintenance of the active list for kidney transplant includes 
a complement -dependent cytotoxity (CDC) panel -reactive antibody (PRA) screening method, and Luminex 
technology for detecting and characterizing HLA alloantibodies. Under the current Portuguese kidney alloca-
tion system from deceased donors, implemented in August 2007, deceased donor kidneys are primarily 
allocated via ABO identical and time on dialysis with extra points to hyperimmunized patients, namely PRA 
CDC > 50%. Additional risk for the candidate or transplant organ can be represented by a proposed calcu-
lated PRA (cPRA) based upon unacceptable HLA antigens detected by Luminex to which the patient has 
been sensitized. These unacceptable HLA antigens used to generate cPRA represents a ‘virtual’ crossmatch 
(XM). Sensitized patients are less likely to be matched with a suitable donor organ. Even after clearing the 
hurdle of procuring a living donor, it is still possible that this is not sufficient due to the likelihood of hav-
ing an XM -positive. In such cases, and in the presence of incompatible blood type between recipients and 
their intended living donors, kidney paired donation (KPD) can provide an answer to this catch by facilitat-
ing exchanges between willing donors’ kidneys. A national Portuguese KPD programme, when realized, may 
prevent the current loss of a significant number of suitable living donors and reduce waiting list time for 
a deceased donor. An upgrade of a suggested point system in a Portuguese KPD programme will be the 
use of cPRA instead of the values of PRA CDC. In Portugal, the virtual XM approach just represents the 
optimization of an existent technique.
RESUMO 
A presença de anticorpos anti -HLA específicos do dador é geralmente uma contraindicação para trans-
plante e, hoje em dia, a identificação destes anticorpos é parte de muitos protocolos de avaliação pré-
-transplante. Em Portugal, o protocolo implementado para o registo e manutenção em lista activa para 
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INTRODUCTION 
The demand for kidneys for transplantation grows 
daily due to the successful treatment of many patients 
with end stage renal disease. The limited number of 
organs available for transplantation requires that 
their distribution be made as equitable as possible 
in order to optimize the use of this scarce resource. 
A fair and appropriate distribution of available organs 
for transplantation continues to be a relevant issue 
and an important topic of debate. If the utilitarian 
argument for the distribution of organs argues that 
they should be transplanted in candidates predicted 
to live longer, then the argument of justice or fair-
ness requires that all transplant candidates have 
equal opportunity of transplantation.
The success of kidney transplants depends largely 
on genetic and immunological compatibility between 
the organ and its recipient. An important barrier to 
kidney transplantation is the sensitization of trans-
plant candidates to human leukocyte antigen (HLA). 
Anti -HLA antibodies develop after exposure to HLA 
antigens, typically following a blood transfusion, 
pregnancy, or a previous transplant. And, many 
hypersensitized patients do not find an acceptable 
donor for transplantation, remaining on dialysis 
indefinitely.
DONOR SPECIFIC ANTIBODIES 
Pre -existing HLA donor specific antibodies (DSA) 
are known to be significant determinants of kidney 
transplant outcome1.
The presence of DSA anti -HLA is generally a con-
traindication for transplantation and, nowadays, the 
identification of these antibodies is part of most 
pre -transplantation evaluations2. The presence of 
preformed HLA DSA has been associated with higher 
risk for hyperacute rejection, accelerated acute rejec-
tion, antibody -mediated rejection, delayed graft func-
tion3 and lower allograft survival4. These findings 
have lead clinicians to periodic DSA screening of all 
transplant recipients in order to discover those pre-
senting these antibodies5.
Several techniques are available to detect these 
DSA. Luminex (Luminex, Austin, Texas, USA) is a 
solid -phase assay using micro -spheres and is more 
sensitive to detect HLA antibodies than conventional 
tests. Luminex mean fluorescence intensity (MFI) as 
a measurement of DSA strength can predict positive 
crossmatch results6. Eventually, results using this 
method could aid in the stratification of immunologi-
cal risks lending added qualification during the clini-
cal decision -making process7.
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transplante de rim, inclui um método de pesquisa em painel reactivo de anticorpos (PRA) por citotoxicidade 
dependente do complemento (CDC) e a tecnologia Luminex para detectar e caracterizar aloanticorpos HLA. 
Segundo as actuais normas para a selecção do par dador -receptor em homotransplantação com rim de 
cadáver, implementadas em Agosto de 2007, a distribuição destes órgãos é prioritariamente isogrupal, 
contabilizando o tempo em diálise com pontos extra paras doentes imunizados, nomeadamente PRA CDC> 
50%. Um risco adicional para os candidatos a transplante de órgãos pode ser representado pelo proposto 
PRA calculado (cPRA), que tem por base antigénios HLA não aceitáveis, detectados por Luminex e para os 
quais os doentes estão sensibilizados. Estes antigénios HLA não aceitáveis usados para gerar o cPRA rep-
resentam um crossmatch (XM) virtual. Os doentes sensibilizados têm uma menor probabilidade de encontrar 
um dador de órgãos admissível e mesmo depois de ultrapassada a barreira de encontrar um dador vivo 
disponível, é possível que isto não seja suficiente devido ao risco elevado de ter um XM positivo. Nestes 
casos e quando há incompatibilidade ABO entre um receptor e o seu potencial dador vivo, a troca de 
dadores vivos de rim (TDR) pode ser a resposta a este problema facilitando a consumação de transplantes 
compatíveis. Um programa nacional de TDR, quando implementado, pode evitar o actual desperdício de 
possíveis dadores vivos de rim e potencialmente reduzir o tempo de espera em lista para transplante com 
dador cadáver. Uma melhoria a um sugerido sistema de pontuação num programa Português de TDR será 
a utilização do cPRA em substituição dos valores de PRA CDC. Em Portugal, a abordagem de XM -virtual 
apenas representa a optimização de técnicas já existentes.
Nefro - 27-2 - MIOLO.indd   78 26-06-2013   15:08:01
Port J Nephrol Hypert 2013; 27(2): 77-81    79
CMYKP
Hypersensitized candidates to kidney transplantation in Portugal
In Portugal, the regulatory circular 01/DQS, of the 
7th January 2009, issued by the Directorate General 
of Health, defines the protocol for the registration 
and maintenance of active list candidates for kidney 
transplantation in both the initial evaluation of 
patients (ABO blood group and HLA typing) and in 
its quarterly review. This protocol includes a 
complement -dependent cytotoxicity (CDC) panel-
-reactive antibody (PRA) screening method, and 
Luminex technology for detecting and characterizing 
HLA alloantibodies.
Hyper -sensitized patients have lower chances of 
transplantation once they are more likely to have a 
positive crossmatch (XM) with an available donor for 
kidney transplantation. The undesirable effects of broad 
allosensitization can be minimized by many comple-
mentary approaches, such as: kidney paired donation 
(KPD), priority allocation on the deceased donor wait-
list, and/or desensitization or XM conversion7.
The current Portuguese kidney allocation system 
from deceased donors was implemented in August 
2007 (Ordinance no. 6537/2007 of 3rd April). Under 
this allocation system, deceased donor kidneys are 
primarily allocated via ABO identical and a scoring 
criteria as following: hyper -immunized patients, 
namely PRA CDC > 50% as 4 and > 80% as 8 points; 
time on the waiting list as 0.1 points/month; and for 
HLA mismatches from 12 (without mismatches) to 1 
point (more than two mismatches).
Additional risk for the candidate or transplant 
organ can be represented by a proposed calculated 
PRA (cPRA) based upon unacceptable HLA antigens 
to which the patient has been sensitized 3. It would 
be a more accurate measure for the definition of 
hyper -immunized patients, according to the protocol 
implemented for Portuguese kidney transplant can-
didates. This proposed cPRA is calculated with HLA 
antigen frequencies of kidney donors and represents 
the percentage of donors that express one or more 
of the antigens unacceptable for a given transplant 
candidate3. In Portugal, a cPRA can be calculated 
with HLA antigen frequencies of voluntary bone mar-
row donors8, because most (if not all) donors are 
in fact potential deceased organ donors and because 
their HLA frequencies are already available9.
The cPRA gives us the probability of each transplant 
candidate to have an XM -positive with the next 
available deceased donor for kidney transplantation. 
Thereby, those patients with higher probabilities 
should receive extra points in the Portuguese alloca-
tion system for kidney transplantation with deceased 
donors. Even better than determining a probability of 
an XM -positive, is knowing whether or not a candidate 
will have a definite XM -positive with the available 
donor in real -time. The unacceptable HLA antigen, 
against which the recipient has antibodies, used to 
generate cPRA represents a ‘virtual’ crossmatch (XM)10. 
With the implementation of these measures, money 
and time will be saved by not performing some real 
XMs at allocation of the deceased donors.
VIRTUAL CROSSMATCH 
The virtual XM is based on the characterization 
of acceptable HLA mismatches in pre -sensitized 
recipients and reflects an attempt to increase the 
donor pools and eliminate the need for a conven-
tional XM6.
In order to calculate the likelihood of a suitable 
XM -negative transplant, it is paramount to obtain a 
detailed characterization of individual HLA antibody 
profiles7.
In Eurotransplant kidney allocation system (ETKAS) 
a special program was established in order to man-
age highly immunized patients (PRA CDC > 85%), the 
Acceptable Mismatch (AM) programme. This pro-
gramme identifies HLA antigens against which the 
patient waiting for a transplant has not yet developed 
allo -antibodies and, therefore, is less likely to have 
a positive XM. Luminex based antibodies specificities 
are excluded from the AM programme because it 
would result in a huge increase in the number of 
highly sensitized patients, affecting the exceptionality 
of the programme11.
For the implementation of the cPRA, an MFI thresh-
old for defining unacceptable antigens should be 
set. Although definition of a cutoff for evaluation of 
the strength of anti -HLA antibodies through Luminex 
MFI can be controversial, it is an essential tool in 
virtual XM.
Pre -transplant DSA HLA antibodies with MFI values 
above 100012 had been proposed as high risk for 
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transplantation and an MFI value higher than 1500 
for DSA has been shown to have a statistical impact 
in graft survival4.
Even though the use of cPRA and virtual XM raises 
undeniable issues, it is also the benchmark of instru-
mental advancement in organ allocation algorithms, 
including the definition of appropriate threshold values 
for antibody assignment and recognition of relevant 
antibodies also to HLA -Cw*, HLA -DQ*, and HLA -DP*.
However, the utility of virtual XM does not replace 
the requirement for actual XM testing before trans-
plantation, to attest the inexistence of immunologic 
incompatibility.
LIVING DONOR TRANSPLANT 
Living donor transplants have been documented 
as a better solution for end stage renal disease 
(ESRD) patients when compared with deceased donor 
transplants13. Also, for living donors, risks are mini-
mal due to technical improvements.
Despite improved graft function and longevity, 
live donor kidney transplants (LDKT) are only a mod-
erate portion of kidney transplants performed in 
Portugal14.
Knowledge of how to ask someone to donate was 
one of the barriers identified by transplant candi-
dates15 to LDKT. The unwillingness of the candidates 
to seek potential donors or their inability to motivate 
these donors16 is other identified barrier. Concerns 
surrounding donor morbidity have also been noted 
in patients with ESRD15. It has been indicated that 
having former donors speaking to potential donors 
could assuage these concerns, thereby improving 
LDKT numbers17.
Older ESRD patients and those with low -income 
have been indicated as being less likely to have a 
potential living donor. On the other hand, greater 
self -efficacy (defined as a person’s belief in their 
capabilities to attract a donor) was a strong predictor 
for having a potential living donor16.
To further boost living kidney donation, measures 
have been proposed to tackle the aforementioned 
issues affecting recipients and donors pre - and post - 
transplant fears and for alleviating patients guilt. 
Educational programmes have been implemented to 
raise awareness about living kidney donation and 
its benefits while at the same time coaching patients 
through asking for a donation15.
Sensitized patients are less likely to be matched 
with a suitable donor organ just via the Portuguese 
allocation system for deceased donors. After clearing 
the hurdle of procuring a living donor, it is still possible 
that this is not sufficient due to the likelihood of hav-
ing an XM -positive. In these cases and in the presence 
of incompatible blood type between recipients and 
their intended living donors, kidney paired donation 
(KPD) can provide an answer to this catch by facilitat-
ing exchanges between willing donors’ kidneys18.
A large pool of incompatible donor -recipient pairs 
promotes better matching outcomes while maximizing 
pool size for the establishment of national KPD pro-
grammes. Also, a central coordination and a central 
laboratory responsible for immunological study of 
donors and recipients are guarantees of success for 
such kinds of programmes19.
A national Portuguese programme, when realized, 
may prevent the current loss of a significant number 
of suitable living donors and, thereby, have a sig-
nificant impact in reducing waiting list time for a 
deceased donor18. An upgrade of a suggested point 
system in a Portuguese living donor exchange pro-
gramme19 will be the use of cPRA instead of the 
values of PRA CDC.
Applying virtual XM rules in KPD has been sug-
gested20. The HLA antibody at a strength of > 2000MFI 
and listing in the pool donor HLA antigens and recipi-
ents HLA antibodies at high -resolution level are rec-
ommended when using virtual XM in KPD20. Virtual 
XM in KPD will reduce the number of matched pairs 
having a positive crossmatch (using both CDC or 
flow cytometry techniques) and, therefore, reduce 
the number of breakdown chains.
CONCLUSIONS 
The Virtual XM approach in combination with cPRA 
represents progress when dealing with hypersensitized 
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patients waiting for a kidney transplant, particularly 
in kidney transplantation with living donors, where 
donors and patients can be HLA genotyped at high-
-resolution level. Also, with the implementation of a 
KPD programme in Portugal, virtual XM will be vital 
to assure its success. In Portugal, the virtual XM 
approach only represents the optimization of an exis-
tent technique.
Conflict of interest statement. None declared.
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